← All trials
NCT05449834
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2022
- Primary completion
- Jun 1, 2026
- Completion date
- Dec 1, 2026
- First posted
- Jul 8, 2022
- Last posted
- Jul 12, 2022
- Enrollment
- 850
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Monash UniversityLead sponsor
- Monash UniversityOverall official - principal investigator
- Australian Red CrossCollaborator
- Australian and New Zealand Intensive Care Society Clinical Trials GroupCollaborator
- Australasian College for Emergency MedicineCollaborator
- Australasian Trauma SocietyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.